Adamantane-derived drugs have been used for treatment and prophylaxis of influenza A virus infection for many years worldwide. Rapid surveillance of antiviral drug resistance is important for appropriate clinical guideline development. Here, we retrospectively assessed adamantane resistance among different influenza A subtypes (H1N1, H3N2 and H5N1) over 53 years (1956–2009) in mainland China.
Methods
A total of 1,451 viruses, including 773 H3N2 viruses, 647 H1N1 viruses and 31 human H5N1 viruses, were analysed by matrix gene sequencing and assayed for drug resistance.
Results
Our results show that the prevalence of adamantane- resistant H3N2 viruses was low between 1956 and 2002, but substantially increased in 2003 to the extent that since 2006 all H3N2 viruses have been drug resistant. The percentage of adamantane- resistant H1N1 viruses also increased from 50.0% in 2004 to 98.7% in 2007; however, this decreased to 46.7% in 2009. Only three adamantane-resistant H5N1 viruses have been detected since 2003, when the first case of human H5N1 virus infection was detected in mainland China. Phylogenetic analysis demonstrated that the increase of adamantane-resistant isolates was caused by point mutations or intrasubtype reassortment instead of intersubtype reassortment.
Conclusions
Because of the high percentage of adamantane- resistant H3N2 and H1N1 viruses in mainland China, the use of amantadine and rimantadine drugs for prophylaxis and treatment of current seasonal influenza A infection is not recommended.
References
1.
DeydeV.M., XuX., BrightR.A.Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.J Infect Dis2007; 196: 249–257.
2.
IzurietaH.S., ThompsonW.W., KramarzP.Influenza and the rates of hospitalization for respiratory disease among infants and young children.N Engl J Med2000; 342: 232–239.
3.
TominackR.L., HaydenF.G.Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections.Infect Dis Clin North Am1987; 1: 459–478.
4.
DolinR., ReichmanR.C., MadoreH.P., MaynardR., LintonP.N., Webber-JonesJ.A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.N Engl J Med1982; 307: 580–584.
5.
TsiodrasS., MooneyJ.D., HatzakisA.Role of combination antiviral therapy in pandemic influenza and stockpiling implications.BMJ2007; 334: 293–294.
6.
WangC., TakeuchiK., PintoL.H., LambR.A.Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block.J Virol1993; 67: 5585–5594.
7.
SuzukiH., SaitoR., MasudaH., OshitaniH., SatoM., SatoI.Emergence of amantadine-resistant influenza A viruses: epidemiological study.J Infect Chemother2003; 9: 195–200.
8.
BelsheR.B., SmithM.H., HallC.B., BettsR., HayA.J.Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.J Virol1988; 62: 1508–1512.
9.
HayA.J., ZambonM.C., WolstenholmeA.J., SkehelJ.J., SmithM.H.Molecular basis of resistance of influenza A viruses to amantadine.J Antimicrob Chemother1986; 18 Suppl B: 19–29.
10.
BrightR.A., MedinaM.J., XuX.Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.Lancet2005; 366: 1175–1181.
11.
SaitoR., SuzukiY., LiD.Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006–2007 influenza season in Japan.J Infect Dis2008; 197: 630–632. Author reply 632–633.
12.
BrightR.A., ShayD.K., ShuB., CoxN.J., KlimovA.I.Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States.JAMA2006; 295: 891–894.
YuH., ShuY., HuS.The first confirmed human case of avian influenza A (H5N1) in Mainland China.Lancet2006; 367: 84.
15.
ShuY., YuH., LiD.Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China.N Engl J Med2006; 354: 1421–1422.
16.
ZhuQ.Y., QinE.D., WangW.Fatal infection with influenza A (H5N1) virus in China.N Engl J Med2006; 354: 2731–2732.
17.
CheungC.L., RaynerJ.M., SmithG.J.Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.J Infect Dis2006; 193: 1626–1629.
18.
HeG., QiaoJ., DongC., HeC., ZhaoL., TianY.Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China.Antiviral Res2008; 77: 72–76.
19.
RoweT., AbernathyR.A., Hu-PrimmerJ.Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.J Clin Microbiol1999; 37: 937–943.
20.
SaikiR.K., GelfandD.H., StoffelS.Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.Science1988; 239: 487–491.
21.
FelsensteinJ.Mathematics vs. evolution: mathematical evolutionary theory.Science1989; 246: 941–942.
22.
FuruseY., SuzukiA., KamigakiT., ShimizuM., FujiN., OshitaniH.Reversion of influenza A (H3N2) virus from amantadine resistant to amantadine sensitive by further reassortment in Japan during the 2006-to-2007 influenza season.J Clin Microbiol2009; 47: 841–844.
23.
FuruseY., SuzukiA., KishiM.Occurrence of mixed populations of influenza A viruses that can be maintained through transmission in a single host and potential for reassortmant.J Clin Microbiol2009; 48: 369–374.
24.
NelsonM.I., ViboudC., SimonsenL.Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918.PLoS Pathog2008; 4: e1000012.
25.
FuruseY., SuzukiA., KamigakiT., OshitaniH.Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis.Virol J2009; 6: 67.
26.
BarrI.G., DengY.M., IannelloP., HurtA.C., KomadinaN.Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.Antiviral Res2008; 80: 200–205.
World Health Organization Europe.WHO/Europe influenza surveillance (EuroFlu.org). (Updated 8 January 2010. Accessed 28 December 2009.) Available from http://www.euroflu.org/index.php.
